Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9

Spiros C. Denaxas | J. Pell | O. Franco | A. Hofman | A. Uitterlinden | C. Carty | A. Reiner | H. Hakonarson | T. Hansen | O. Pedersen | N. Grarup | S. Yusuf | P. Ridker | D. Chasman | H. Völzke | John Wright | S. Humphries | H. Goldschmidt | A. Hingorani | B. Horta | A. Dehghan | G. Morgan | P. Sonneveld | C. McCarty | B. Nilsson | D. Roden | R. Scott | D. Grobbee | P. Whincup | N. Sattar | H. Snieder | M. Sanson | E. Ingelsson | R. Houlston | P. Froguel | S. Coassin | L. Lind | M. O’Donnell | J. Denny | M. Brilliant | K. Hemminki | N. Wareham | A. Mahajan | S. Gustafsson | C. Power | P. Marques‐Vidal | S. Kiechl | J. Willeit | M. Ritchie | A. Nicolaides | M. Bots | G. Matullo | A. Teumer | U. Völker | T. Kitchner | L. Bertram | S. Baumeister | J. Attia | M. de Andrade | E. Holliday | E. Larson | S. Seshadri | F. Hartwig | A. Campbell | J. Luan | S. Padmanabhan | M. A. Said | R. Scott | R. N. Eppinga | C. Langenberg | P. van der Harst | D. Mook-Kanamori | C. Lill | T. Meade | A. Bonnefond | Y. Ben-Shlomo | K. Hovingh | J. Price | M. Kumari | M. Kivimaki | E. Steinhagen-Thiessen | H. Hemingway | I. Demuth | Riyaz S. Patel | Sara E Dobbins | G. Paré | M. Bobák | J. Casas | R. Kubínová | A. Linneberg | S. Malyutina | S. McLachlan | A. Pająk | H. Pikhart | A. Tamosiunas | M. Lerch | M. Dörr | H. Speedy | P. Law | J. Allan | D. Carrell | R. Roussel | N. Verweij | I. Ford | E. Hypponen | F. Asselbergs | L. Lange | R. Young | J. Ward | M. Holmes | R. Morris | G. Fiorito | S. Guarrera | M. Andrade | Y. T. van der Schouw | N. Onland-Moret | C. Sacerdote | D. Thuillier | J. Hopewell | M. Bondy | R. Pazoki | J. Cooper | Y. Bao | M. Smart | B. Keating | D. Crosslin | G. Fatemifar | T. Lumbers | K. Labreche | C. Finan | A. Panayiotou | K. Willeit | P. Schofield | A. H. Maitland‐van der Zee | D. Mason | B. Cariou | K. Norman | M. Simon | M. Hansson | Albert Henry | T. Jess | C. Dale | M. Chong | Stephen J Hancock | D. Preiss | A. Cornish | M. Went | B. Kinnersley | N. Weinhold | Ni L Li | A. Sud | D. Swerdlow | M. Moldovan | Z. Fairhurst-Hunter | A. Schmidt | I. Christophersen | A. Engert | E. V. van Iperen | C. Welch | Sara E. Dobbins | R. Faraway | D. Valentine | Juri Demuth | Goya Wanamethee | A. Sánchez-Gálvez | Kirchner H. Lester | T. Christen | E. Baranova | R. P. E. Costa

[1]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[2]  Deepak L. Bhatt,et al.  Cardiovascular Outcomes With Alirocumab After Acute Coronary Syndrome: Results of the Odyssey Outcomes Trial , 2018 .

[3]  A. Sposito,et al.  Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years , 2017, Diabetes Care.

[4]  P. Deloukas,et al.  Impact of Selection Bias on Estimation of Subsequent Event Risk , 2017, Circulation. Cardiovascular genetics.

[5]  R. Giugliano,et al.  Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Circulation.

[6]  A. Keech,et al.  Cognitive Function in a Randomized Trial of Evolocumab , 2017, The New England journal of medicine.

[7]  Stephen Burgess,et al.  Mendelian randomization with fine‐mapped genetic data: Choosing from large numbers of correlated instrumental variables , 2017, Genetic epidemiology.

[8]  E. Boerwinkle,et al.  Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study. , 2017, The lancet. Diabetes & endocrinology.

[9]  John P. Overington,et al.  PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. , 2017, The Cochrane database of systematic reviews.

[10]  B. Tomlinson,et al.  Alirocumab for the treatment of hypercholesterolemia , 2017, Expert opinion on biological therapy.

[11]  Hynek Pikhart,et al.  PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study , 2017, The lancet. Diabetes & endocrinology.

[12]  Szilard Voros,et al.  Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. , 2016, The New England journal of medicine.

[13]  Peter Sandercock,et al.  Interpretation of the evidence for the efficacy and safety of statin therapy , 2016, The Lancet.

[14]  Sara M. Willems,et al.  Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.

[15]  S. Humphries,et al.  Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. , 2016, JAMA cardiology.

[16]  Mengting Zhu,et al.  Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke , 2015, The International journal of neuroscience.

[17]  Riyaz S. Patel,et al.  The GENIUS-CHD consortium. , 2015, European heart journal.

[18]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[19]  C. Le May,et al.  Role of PCSK9 beyond liver involvement , 2015, Current opinion in lipidology.

[20]  R. Mägi,et al.  Using Genetic Variants to Assess the Relationship Between Circulating Lipids and Type 2 Diabetes , 2015, Diabetes.

[21]  Hynek Pikhart,et al.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[22]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[23]  J. Shendure,et al.  A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.

[24]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[25]  A. Shaywitz,et al.  Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. , 2012, Journal of the American College of Cardiology.

[26]  A. Butterworth,et al.  Use of Mendelian randomisation to assess potential benefit of clinical intervention , 2012, BMJ : British Medical Journal.

[27]  Jennifer G. Robinson,et al.  The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.

[28]  J. Danesh,et al.  Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data , 2011, BMJ : British Medical Journal.

[29]  Børge G Nordestgaard,et al.  PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses. , 2010, Journal of the American College of Cardiology.

[30]  Jackie A Cooper,et al.  PLA2G7 Genotype, Lipoprotein-Associated Phospholipase A2 Activity, and Coronary Heart Disease Risk in 10 494 Cases and 15 624 Controls of European Ancestry , 2010, Circulation.

[31]  Yasuo Ohashi,et al.  Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials , 2010, The Lancet.

[32]  Meena Kumari,et al.  Separating the Mechanism-Based and Off-Target Actions of Cholesteryl Ester Transfer Protein Inhibitors With CETP Gene Polymorphisms , 2010, Circulation.

[33]  R. Collins,et al.  Newly identified loci that influence lipid concentrations and risk of coronary artery disease , 2008, Nature Genetics.

[34]  A. Rabinstein.  Efficacy and safety of cholesterol-lowering treatment: prospective metaanalysis of data from 90 056 participants in 14 randomised trials of statins , 2007 .

[35]  M. Hennerici,et al.  High-dose atorvastatin after stroke or transient ischemic attack. , 2006, The New England journal of medicine.

[36]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[37]  A. Hingorani,et al.  Nature's randomised trials , 2005, The Lancet.

[38]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[39]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[40]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[41]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..